• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:汤于婷,沈瑛.ACAT1/2促进非小细胞肺癌对KRAS G12C抑制剂耐药[J].药学研究,2026,45(5):481-487,541[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1546次   下载 841次 本文二维码信息
码上扫一扫!
ACAT1/2促进非小细胞肺癌对KRAS G12C抑制剂耐药
汤于婷,沈瑛
字体:加大+|默认|缩小-
(上海交通大学医学院药理学与化学生物学系,上海 200025)
摘要:
目的 探讨酰基辅酶A:胆固醇酰基转移酶1/2(ACAT1/2)在KRAS G12C抑制剂获得性耐药中的作用,为逆转非小细胞肺癌(NSCLC)对该类药物的耐药提供潜在靶点。方法 通过大剂量药物冲击法构建Sotorasib获得性耐药细胞;采用免疫印迹法检测ACAT1和ACAT2在亲本和耐药细胞中的蛋白表达水平;采用ACAT1/2抑制剂Avasimibe处理细胞,通过CCK-8法检测细胞活力,评估Avasimibe单药对亲本及耐药细胞增殖的抑制作用,并进一步考察Avasimibe联合Sotorasib对耐药细胞药物敏感性的影响,通过协同系数分析两药的相互作用。结果 成功构建Sotorasib获得性耐药细胞,与亲本细胞相比,H358SoR和H2122SoR对Sotorasib的半数抑制浓度(IC50)显著增加。免疫印迹证实耐药细胞中ACAT1和ACAT2蛋白水平均明显升高。Avasimibe可剂量依赖性抑制亲本及耐药细胞增殖,且对耐药细胞的抑制作用显著强于亲本细胞。联合用药实验中,Avasimibe与Sotorasib联用部分恢复耐药细胞对Sotorasib的敏感性;协同系数分析表明,在多个浓度组合下,两药的协同系数(CI)均小于1,显示出协同抑制的效果。结论 ACAT1和ACAT2在KRAS G12C抑制剂获得性耐药NSCLC细胞中表达上调,靶向ACAT1/2可选择性抑制耐药细胞增殖并部分恢复药物敏感性。ACAT1/2可能通过调控胆固醇代谢参与耐药形成,联合抑制ACAT1/2有望成为克服KRAS G12C抑制剂耐药的新策略。
关键词:  酰基辅酶A:胆固醇酰基转移酶1  酰基辅酶A:胆固醇酰基转移酶2  KRAS G12C抑制剂  获得性耐药  非小细胞肺癌  代谢编程
DOI:10.13506/j.cnki.jpr.2026.05.001
基金项目:国家自然科学基金面上项目(No.82473936)
收稿日期:2026-03-09   修回日期:2026-03-26   出版日期:2026-05-29
ACAT1/2 promote resistance of non-small cell lung cancer to KRAS G12C inhibitor
TANG Yuting,SHEN Ying
(Department of Pharmacology and Chemical Biology, Shanghai Jiaotong University School of Medicine, Shanghai 200025,China)
Abstract:
Objective To investigate the role of acetyl-CoA: cholesterol acetyltransferase 1/2 (ACAT1/2) in acquired resistance to KRAS G12C inhibitors and to provide a potential target for reversing resistance in non-small cell lung cancer (NSCLC). Methods Sotorasib-resistant cell were established by high-dose drug exposure. Protein expression levels of ACAT1 and ACAT2 were detected by Western blotting. Cells were treated with the ACAT1/2 inhibitor Avasimibe, and cell viability was assessed using the CCK-8 assay to evaluate the inhibitory effect of Avasimibe alone on the proliferation of parental and resistant cells. The effect of Avasimibe in combination with Sotorasib on the drug sensitivity of resistant cells was further examined, and the drug interaction was analyzed using the combination index (CI). Results Sotorasib-resistant cell lines were successfully established, showing significantly increased half maximal inhibitory concentration (IC50) values for Sotorasib compared to parental cells. Western Blot confirmed markedly elevated protein levels of both ACAT1 and ACAT2 in resistant cells. Avasimibe inhibited the proliferation of both parental and resistant cells in a dose-dependent manner, with significantly stronger inhibitory effects observed in resistant cells. In combination experiments, Avasimibe partially restored the sensitivity of resistant cells to Sotorasib. Combination index analysis showed CI values less than 1 across multiple concentration combinations, indicating synergistic inhibitory effects. Conclusion ACAT1 and ACAT2 are upregulated in NSCLC cells with acquired resistance to KRAS G12C inhibitors. Targeting ACAT1/2 selectively inhibits the proliferation of resistant cells and partially restores drug sensitivity. ACAT1/2 may contribute to resistance formation by regulating cholesterol metabolism, and combined inhibition of ACAT1/2 represents a potential strategy to overcome resistance to KRAS G12C inhibitors.
Key words:  Acetyl-CoA:Cholesterol acetyltransferase 1(ACAT1)  ACAT2  KRAS G12C inhibitor  Acquired resistance  Non-small cell lung cancer
今日访问量:2273    总访问量:55338614
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司